This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Magnolia Bark
Magnolia officinalis bark extract — standardized to honokiol + magnolol (the two biphenyl neolignans that do the work) — is one of the better-evidenced PM-only botanicals for sleep-onset, evening a…
Aliases (1)
Overview
What is Magnolia Bark?
Magnolia officinalis bark extract — standardized to honokiol + magnolol (the two biphenyl neolignans that do the work) — is one of the better-evidenced PM-only botanicals for sleep-onset, evening anxiolysis, and salivary cortisol blunting. Mechanism is real and triangulated: GABA-A positive allosteric modulation at the benzodiazepine site (flumazenil-reversible in rodents), CB1 partial agonism (CB1-antagonist-reversible), and glucocorticoid-axis attenuation. Human RCTs are small (Kalman 2008 PMID 18426577; Talbott 2013 PMID 23924268) but consistent: cortisol drops ~18%, state anxiety drops, sleep onset shortens. Dose: 200–500 mg/day standardized extract, 30–60 min pre-sleep, ≤8 weeks continuous then assess. Skip if on benzos, z-drugs, opioids, or alcohol same night; pregnancy is a hard block on theoretical uterotonic + thin data. For Dylan (20yo MMA athlete, night-owl, high evening cortisol) the verdict is OPTIONAL-ADD: pairs well with the existing magnesium-glycinate + L-theanine wind-down and earns its place on heavier-stress nights without the dependence trap of phenibut or the prescription pathway of trazodone.
Pharmacokinetics
Peptide Interactions
already in Dylan's stack. Different mechanism (presynaptic glutamate modulation, α-wave EEG). Pairs cleanly without overlap.
already in V4 stack. NMDA antagonism + GABA-A modulation. Synergistic for sleep-onset.
already in V4. Inhibitory neurotransmitter, mild thermal effect on sleep onset.
GABA-A benzo-site PAM (same mechanism site as magnolia). Some users find redundancy useful; risk of additive sedation at higher doses.
GABA transaminase inhibitor. Different mechanism. Good rotation partner.
cortisol-blunting via separate mechanism (likely 5-HT2A modulation + GABA-mimetic). Synergistic for HPA-axis attenuation, dosed AM or PM.
co-formulated for cortisol synergy. The Relora data is the *combination* data; standalone magnolia data is more limited.
Additive GABA-A activity at the same binding site. Risk of excessive sedation and respiratory depression at higher doses. Avoid same-day combination.
Same concern as benzos. Avoid.
GABA-B agonism + magnolia's GABA-A activity — risk of compounded sedation and tolerance acceleration. (Phenibut is independently a SKIP-PERMANENT in this arc…
Strongly additive CNS depression. Avoid same-night use.
Additive sedation + respiratory depression at higher doses. Avoid combination unless medically supervised.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety 6
Side Effects
- 1Drowsiness next-morning (15–25% at 500mg+, less at 250mg) — usually fades within a week of consistent dosing. Mitigations: drop dose, dose earlier in evening (1.5–2 hr pre-sleep instead of 30 min).
- 2GI upset (transient nausea, loose stools) — 5–10% of users. Take with light food if it persists.
- 3Vivid dreams or REM-rebound on discontinuation — anecdotal, consistent with GABA-A modulation withdrawal in animal studies.
- 4Paradoxical anxiety / agitation — community data 16/239 reports. Mechanism unclear (subtype-selectivity heterogeneity, individual GABA-A composition). Drop dose or discontinue.
- 5Headache — 2–5%, usually first 1–3 doses.
- 6Dry mouth, mild dizziness — rare.
When to Stop
- Hepatotoxicity — no clinical reports in well-conducted trials at supplement doses, but case reports of mild ALT/AST elevation in users on high-dose long-term magnolia + other botanicals exist (typically multi-herb confounders, not isolated magnolia).
- Profound sedation in combination with CNS depressants — see Drug Interactions. Not "rare" in the combination case; "rare" only because the population using magnolia without checking the stack overlap is small.
- Pregnancy / lactation — limited human data, theoretical uterotonic effects in animal models. Hard block during pregnancy.
- Weeks 1–2: paradoxical-anxiety calibration — if a user gets stimulation/anxiety rather than calm at standard dose, stop and reassess. Try a single 100mg test dose first if anxiety-prone.
- Weeks 4–8: sedation tolerance check — if morning drowsiness persists past week 2, drop dose; if drowsiness *increases* despite dose stability (rare, indicates accumulation), discontinue and reassess.
- Months 3+: tolerance / efficacy fade — cycle off for 1–2 weeks every 6–8 weeks to verify continued benefit; the benzo-site mechanism makes tolerance theoretically possible, even if clinical evidence of tolerance is sparse.
References
Kalman et al. 2008 — Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women
PMID 18426577, Nutr J. RCT, 6 weeks, 750mg Relora/day. Significant reduction in state anxiety.
View StudyTalbott et al. 2013 — Effect of Magnolia officinalis and Phellodendron amurense (Relora®) on cortisol and psychological mood state
PMID 23924268, J Int Soc Sports Nutr. RCT, 4 weeks, 56 completers. Salivary cortisol ↓ 18%, broad mood improvements.
View StudyQu et al. 2012 — Magnolol induces sleep via the benzodiazepine site of GABA-A in mice
PMID 22771461. Mechanism + flumazenil reversibility.
View StudyQu et al. 2012 — Honokiol promotes NREM sleep via the benzodiazepine site of GABA-A
PMC3449263, Br J Pharmacol. Companion paper to magnolol study.
View StudyAlexeev et al. 2012 — Magnolol and honokiol are positive allosteric modulators of synaptic and extra-synaptic GABA-A receptors
PMC3652012. Patch-clamp confirmation of GABA-A modulation, including δ-subunit preference.
View StudyBorgonetti et al. 2021 — Honokiol-enriched Magnolia officinalis bark extract — anxiolytic via CB1 receptor modulation
PMID 33950239, J Pharm Pharmacol. CB1 partial agonism mechanism confirmation + BDNF neuroprotection.
View StudySarrica et al. 2018 — Safety and Toxicology of Magnolol and Honokiol
PMID 29925102, Planta Med. No mutagenic/genotoxic potential, NOAEL >240 mg/kg, up to 1-year human trial safety.
View StudyKuribara et al. 1998 — Behavioural pharmacological characteristics of honokiol — elevated plus-maze in mice
PMID 9720634. Anxiolysis at 0.2 mg/kg after 7-day repeated dosing.
View StudyKuribara et al. 1999 — Honokiol has no diazepam-like side-effects in mice
PMID 10197425. Selective anxiolysis without motor impairment or sedation.
View StudyKuribara et al. 1998 — Identification of magnolol and honokiol as anxiolytic agents in Saiboku-to
PMID 9461663. Active-compound attribution.
View StudyLi et al. 2024 — Recent advances of honokiol — pharmacological activities, derivatives, structure-activity
PMID 38704945, Eur J Med Chem. Modern pharmacology synthesis.
View StudyNeuropharmacological potential of honokiol — Chinese Medicine 2023
Comprehensive 2023 review.
View StudyTaferner et al. 2011 — GABA-A receptor modulation by honokiol and derivatives — subtype selectivity
PMID 21699169. α-subunit selectivity data.
View StudyHonokiol as a next-generation phytotherapeutic — 2025 nanomedicine review
2025 review, anticancer + neuroprotective + delivery systems.
View StudyMucci et al. 2006 — Soy isoflavones, lactobacilli, Magnolia bark, vitamin D3 and calcium in menopause
PMID 16957676. Postmenopausal multi-ingredient sleep/mood trial.
View StudyMagnolol/honokiol structure-activity relationships review 2024
PMID 38714288. Medicinal chemistry of derivatives.
View Studydopamine.club community profile — magnolia bark
239 community reports; #5 sleep, #7 stress, #10 anxiety leaderboard ranks; dose distribution + stack synergies.
View StudyLatest research
- reviewHonokiol as a next-generation phytotherapeutic — anticancer, neuroprotective, and nanomedicine perspectivesSynthesis of preclinical anticancer and neuroprotective evidence plus nanocarrier formulations (liposomes, micelles) addressing honokiol's low oral bioavailability — phase I liposomal honokiol trials underway for glioblastoma.
- reviewRecent advances of honokiol — pharmacological activities, manmade derivatives and structure-activity relationship2024 European Journal of Medicinal Chemistry review consolidates anticancer, anti-inflammatory, neuroprotective, antimicrobial pharmacology; flags poor stability/water-solubility as the limiter for clinical translation of pure honokiol.
- reviewNeuropharmacological potential of honokiol and its derivatives from Chinese herb Magnolia speciesComprehensive Chinese Medicine review covering anxiolysis, sleep, neuroprotection, mood effects; identifies GABA-A benzo-site PAM activity, CB1 partial agonism, and BDNF normalization as core mechanisms.
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.